Ingevity Widens FY2026 Adj EPS Guidance from $4.80-$5.20 to $4.70-$5.20 vs $4.80 Est; Lowers FY2026 Sales Guidance from $1.100B-$1.200B to $1.050B-$1.150B vs $1.187B Est

Benzinga Newsdesk www.benzinga.com Negative 48.1%

Neg 48.1% Neu 0% Pos 0%

Ingevity (NYSE:NGVT) widens FY2026 Adj EPS guidance from $4.80-$5.20 to $4.70-$5.20 vs $4.80 analyst estimate. Lowers FY2026 sales outlook from $1.100 billion-$1.200 billion to $1.050 billion-$1.150 billion vs $1.187 billion estimate.